Skip to main content
. 2017 Jul 29;2(3):e000200. doi: 10.1136/esmoopen-2017-000200

Figure 1.

Figure 1

The guideline for the treatment of non-small cell lung cancer (NSCLC) after the development of immunotherapy.

HHS Vulnerability Disclosure